Yue Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Lin has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Antoun Toubaji2 shared publications
- Baris Turkbey
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
2 shared publications - Bradford J. Wood
Center for Interventional Oncology, NCI, NIH, Bethesda, MD, USA
2 shared publications Charisse Garcia
2 shared publicationsDaguang Xu
2 shared publications- Dong Yang
NVIDIA, Santa Clara, CA 95051, USA
2 shared publications
Latest Publications
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6 (6) , e240050
External Validation of a Previously Developed Deep Learning–based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans
Purpose To evaluate the performance of an artificial intelligence (AI) model in detecting overall and clinically significant prostate cancer (csPCa)-positive lesions on paired external and in-house biparametric MRI (bpMRI) scans and assess performance differences between each dataset. Materials and Methods This single-center retrospective study included patients who underwent prostate MRI at an external institution and were rescanned at the authors' institution between May 2015 and May 2022. A genitourinary radiologist performed prospective readouts on in-house MRI scans following the Prostate Imaging Reporting and Data System (PI-RADS) version 2.0 or 2.1 and retrospective image quality assessments for all scans. A subgroup of patients underwent an MRI/US fusion-guided biopsy. A bpMRI-based lesion detection AI model previously developed using a completely separate dataset was tested on both MRI datasets. Detection rates were compared between external and in-house datasets with use of the paired comparison permutation tests. Factors associated with AI detection performance were assessed using multivariable generalized mixed-effects models, incorporating features selected through forward stepwise regression based on the Akaike information criterion. Results The study included 201 male patients (median age, 66 years [IQR, 62-70 years]; prostate-specific antigen density, 0.14 ng/mL2 [IQR, 0.10-0.22 ng/mL2]) with a median interval between external and in-house MRI scans of 182 days (IQR, 97-383 days). For intraprostatic lesions, AI detected 39.7% (149 of 375) on external and 56.0% (210 of 375) on in-house MRI scans (P < .001). For csPCa-positive lesions, AI detected 61% (54 of 89) on external and 79% (70 of 89) on in-house MRI scans (P < .001). On external MRI scans, better overall lesion detection was associated with a higher PI-RADS score (odds ratio [OR] = 1.57; P = .005), larger lesion diameter (OR = 3.96; P < .001), better diffusion-weighted MRI quality (OR = 1.53; P = .02), and fewer lesions at MRI (OR = 0.78; P = .045). Better csPCa detection was associated with a shorter MRI interval between external and in-house scans (OR = 0.58; P = .03) and larger lesion size (OR = 10.19; P < .001). Conclusion The AI model exhibited modest performance in identifying both overall and csPCa-positive lesions on external bpMRI scans. Keywords: MR Imaging, Urinary, Prostate Supplemental material is available for this article. © RSNA, 2024.
- 1 November 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 6 (6) , e240050
External Validation of a Previously Developed Deep Learning–based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans
Purpose To evaluate the performance of an artificial intelligence (AI) model in detecting overall and clinically significant prostate cancer (csPCa)-positive lesions on paired external and in-house biparametric MRI (bpMRI) scans and assess performance differences between each dataset. Materials and Methods This single-center retrospective study included patients who underwent prostate MRI at an external institution and were rescanned at the authors' institution between May 2015 and May 2022. A genitourinary radiologist performed prospective readouts on in-house MRI scans following the Prostate Imaging Reporting and Data System (PI-RADS) version 2.0 or 2.1 and retrospective image quality assessments for all scans. A subgroup of patients underwent an MRI/US fusion-guided biopsy. A bpMRI-based lesion detection AI model previously developed using a completely separate dataset was tested on both MRI datasets. Detection rates were compared between external and in-house datasets with use of the paired comparison permutation tests. Factors associated with AI detection performance were assessed using multivariable generalized mixed-effects models, incorporating features selected through forward stepwise regression based on the Akaike information criterion. Results The study included 201 male patients (median age, 66 years [IQR, 62-70 years]; prostate-specific antigen density, 0.14 ng/mL2 [IQR, 0.10-0.22 ng/mL2]) with a median interval between external and in-house MRI scans of 182 days (IQR, 97-383 days). For intraprostatic lesions, AI detected 39.7% (149 of 375) on external and 56.0% (210 of 375) on in-house MRI scans (P < .001). For csPCa-positive lesions, AI detected 61% (54 of 89) on external and 79% (70 of 89) on in-house MRI scans (P < .001). On external MRI scans, better overall lesion detection was associated with a higher PI-RADS score (odds ratio [OR] = 1.57; P = .005), larger lesion diameter (OR = 3.96; P < .001), better diffusion-weighted MRI quality (OR = 1.53; P = .02), and fewer lesions at MRI (OR = 0.78; P = .045). Better csPCa detection was associated with a shorter MRI interval between external and in-house scans (OR = 0.58; P = .03) and larger lesion size (OR = 10.19; P < .001). Conclusion The AI model exhibited modest performance in identifying both overall and csPCa-positive lesions on external bpMRI scans. Keywords: MR Imaging, Urinary, Prostate Supplemental material is available for this article. © RSNA, 2024.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (2) , e230750
Evaluation of a Cascaded Deep Learning–based Algorithm for Prostate Lesion Detection at Biparametric MRI
A deep learning–based algorithm automatically detected cancerous lesions on prostate biparametric MRI scans with reasonable performance and reliably predicted clinically significant prostate cancer at biopsy.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (2) , e230750
Evaluation of a Cascaded Deep Learning–based Algorithm for Prostate Lesion Detection at Biparametric MRI
A deep learning–based algorithm automatically detected cancerous lesions on prostate biparametric MRI scans with reasonable performance and reliably predicted clinically significant prostate cancer at biopsy.
- 8 June 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 128 (5) , 781-789
Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer
Background: The aim of this study was to determine if change in stage after neoadjuvant chemoradiation (CRT) was associated with improved survival in esophageal cancer using a national database.Methods: Using the National Cancer Database, patients with non‐metastatic, resectable esophageal cancer who received neoadjuvant CRT and surgery were identified. Comparing clinical to the pathologic stage, change in stage was classified as pathologic complete response (pCR), downstaged, same‐staged, or upstaged. Univariable and multivariable Cox regression models were used to identify factors associated with survival.Results: A total of 7745 patients were identified. The median overall survival (OS) was 34.9 months. Median OS was 60.3 months if pCR, 39.1 months if downstaged, 28.3 months if same‐staged, and 23.4 months if upstaged (p < 0.0001). On multivariable analysis, pCR was associated with improved OS compared to the other groups (downstaged: hazard ratio [HR]: 1.32 [95% confidence interval [CI]: 1.18−1.46]; same‐staged: HR: 1.89 [95% CI: 1.68−2.13]; upstaged: HR: 2.54 [95% CI: 2.25−2.86]; all p < 0.0001).Conclusions: In this large database study, change in stage after neoadjuvant CRT was strongly associated with survival for patients with non‐metastatic, resectable esophageal cancer. There was a significant stepwise decline in survival, in descending order of pCR, downstaged tumor, same‐staged tumor, and upstaged tumor.
- 8 June 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 128 (5) , 781-789
Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer
Background: The aim of this study was to determine if change in stage after neoadjuvant chemoradiation (CRT) was associated with improved survival in esophageal cancer using a national database.Methods: Using the National Cancer Database, patients with non‐metastatic, resectable esophageal cancer who received neoadjuvant CRT and surgery were identified. Comparing clinical to the pathologic stage, change in stage was classified as pathologic complete response (pCR), downstaged, same‐staged, or upstaged. Univariable and multivariable Cox regression models were used to identify factors associated with survival.Results: A total of 7745 patients were identified. The median overall survival (OS) was 34.9 months. Median OS was 60.3 months if pCR, 39.1 months if downstaged, 28.3 months if same‐staged, and 23.4 months if upstaged (p < 0.0001). On multivariable analysis, pCR was associated with improved OS compared to the other groups (downstaged: hazard ratio [HR]: 1.32 [95% confidence interval [CI]: 1.18−1.46]; same‐staged: HR: 1.89 [95% CI: 1.68−2.13]; upstaged: HR: 2.54 [95% CI: 2.25−2.86]; all p < 0.0001).Conclusions: In this large database study, change in stage after neoadjuvant CRT was strongly associated with survival for patients with non‐metastatic, resectable esophageal cancer. There was a significant stepwise decline in survival, in descending order of pCR, downstaged tumor, same‐staged tumor, and upstaged tumor.
- 19 December 2021
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 22 (1) , 111-117
Development and evaluation of cancer differentiation analysis technology: a novel biophysics-based cancer screening method
Routine health checkup is an essential strategy for monitoring population health and maintaining healthy workforces. However, there was a lack of cancer screening tests among routine health checkup...
- 19 December 2021
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 22 (1) , 111-117
Development and evaluation of cancer differentiation analysis technology: a novel biophysics-based cancer screening method
Routine health checkup is an essential strategy for monitoring population health and maintaining healthy workforces. However, there was a lack of cancer screening tests among routine health checkup...
- 1 November 2019
- Published by Elsevier in Value in Health
- Vol. 22, S467-S468
PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA
- 1 November 2019
- Published by Elsevier in Value in Health
- Vol. 22, S467-S468
PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA